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Dexamethasone has a potentiating effect on pheno- 
barbitone mediated induction of cytochrome P-450b + 
e mRNAs in adult rat liver. However, the glucocorti- 
coid inhibits phenobarbitone-activated transcription 
of cytochrome P-450b + e mRNAs by 60-70s. This 
inhibitory effect is evident in run-off transcription of 
the endogenous genes as well as in the transcription of 
an added cloned gene fragment. Dexamethasone inhib- 
its the phenobarbitone-mediated increase in the bind- 
ing of a transcription factor(s) to the upstream region 
of the gene as evidenced by gel retardation and South- 
western blot analysis. The glucocorticoid does not sta- 
bilize the phenobarbitone-induced polyribosomal cy- 
tochrome P-450b + e mRNAs but appears to stabilize 
the nuclear transcripts. It is proposed that a negative 
element may mediate the action of dexamethasone at 
the level of nuclear transcription and stabilization of 
the nuclear transcript may account for the potentiating 
effect of the glucocorticoid on phenobarbitone-me- 
diated increase in cytochrome P-450b + e mRNAs in 
the cytoplasm of the adult rat liver. However, the 
cytochrome P-450b protein levels are slightly lower in 
phenobarbitone+dexamethasone treatment than in 
phenobarbitone-treated liver microsomes. 
A sufficient amount of sequence information at the gene 
level is now available for the cytochrome P-450 supergene 
family to permit investigators to embark on examination of 
the features of regulation of gene expression. In particular, 
cis and trans responsive elements have been identified in the 
5’ upstream region of the 3-methylcholanthrene inducible 
cytochrome P-4501A gene family (l-4). The mechanism of 
induction of the phenobarbitone (PB)‘-inducible cytochrome 
P450IIB gene family (cytochrome P-450b and e in rat liver) 
has not been well studied, except for the finding that the drug 
acts primarily by activating transcription (5, 6). DNA se- 
quence information of the 5’ upstream region of the cyto- 
chrome P-450b/e gene reveals several interesting regulatory 
motifs such as direct and indirect repeats, an alternating 
pyrimidine-purine stretch and potential glucocorticoid re- 
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sponsive core sequences, TGTCCT (7, 8). Recently, studies 
in this laboratory have led to the identification of a PB- and 
heme-modulated transcription factor in rat liver (9). Simmons 
et al. (10) have shown that dexamethasone (Dex, 80 mg/kg 
body weight) increases cytochrome P-450b/e mRNA in rat 
liver by about 12-fold without any significant effect on tran- 
scription and mRNA stabilization has been suggested to be 
the likely reason for this effect. In the present study, we report 
the novel finding that Dex negatively interferes with the PB- 
mediated activation of cytochrome P-4506/e gene transcrip- 
tion but shows a potentiating effect in enhancing the corre- 
sponding mRNA levels. The possible mechanisms of Dex 
action are discussed. 
MATERIALS AND METHODS 
Treatment of Animals-Male rats (80-85 g) of the Institute strain 
were injected with PB (8 mg/lOO g body weight), Dex (5 mg/lOO g) 
and actinomycin D (100 pg/lOO g), intraperitoneally. CoClz. 6HzO (6 
mg/lOO g) was injected subcutaneously. In all the experiments, the 
animals received the various treatments for a period of 6 h, except in 
experiments involving the measurement of cytochrome P-450b pro- 
tein content, where the treatment period was 10 h. 
Cytochrome P-45O(b+e) mRNA Quantification-Total RNA was 
isolated from magnesium precipitated polyribosomes of rat liver by 
phenol/chloroform extraction method (11). Dot blot analysis with 10 
and 20 gg of total polyribosomal RNA was carried out (12) using pP- 
450-91, a cloned cDNA Drobe isolated in this laboratorv (6). In some 
experiments, cytochroie P-450b and e mRNAs were quantified sep- 
arately using oligonucleotide probes as described by Omiecinski et al. 
(13). 
Nuclear Run-off Transcription-This was carried out by the pro- 
cedure of Guertin et al. (14) and has been described pre;iously (6, 
15). Brieflv. nuclei were incubated with 200 uCi of lol-“‘PIUTP and 
other components including human placental RNaie inhibitor in a 
total volume of 200 ~1 for 45 min at 25 “C. The labeled RNA tran- 
scribed was isolated by phenol/chloroform extraction after DNase I 
and proteinase K treatments. pP-450-91 DNA was linearized and 
loaded onto nitrocellulose filters and hybridization carried out with 
the labeled RNA transcripts (10’ cpm). The hybridized radioactivity 
was measured after washing and pancreatic DNase I and RNase Tl 
treatments. oc-Amanatin (1 pg/ml) was added to establish the speci- 
ficity of mRNA transcription. Filters containing pUC19 DNA served 
as controls for nonspecific hybridization. 
Transcription Analysis of Cloned DNA Fragment by Sl Nuclease 
Protection Assay-The plasmid pP-450-e4 containing a 360-bp frag- 
ment of the cytochrome P-450e gene (identical with cytochrome P- 
450b gene except for four base substitutions) cloned into the SmaI 
site of pUC19 -was used. The fragment can be released from the 
plasmid with BamHI and EcoRI (polylinker sites) and contains -179 
nucleotides of the 5’-flanking region and +181 nucleotides of the first 
exon. The fragment has a unique NcoI site at +29 and a SphI site at 
-1 (9). The Dlasmid DNA (3 ua) was added to freeze-thawed rat liver 
nuclei and tianscription carried out as already described except that 
cold UTP replaced the radioactive precursor. The RNA transcripts 
were isolated and hybridized to the NcoI-EcoRI fragment of pP-450- 
e4 which had been labeled at the NcoI end using Klenow polymerase 
(50,000 cpm). S, nuclease protection analysis was carried out as 
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5618 Effect of Dexamethasone on Cytochrome P-450b/e Gene Expression 
described hy Favaloro er a/ (16) and the protected fragment was 
analyzed on urea-polyacrylamide gel electrophoresis (8% acrylamide) 
and subjected to autoradiography. 
Gel Retardation Assay-Nuclei were prepared using citric acid 
buffer homogenization (171 and nuclear extracts were prepared using 
0.45 M NaCl (in final concentration) and dialysis (9). The nuclear 
extract (l-.5 pg of protein) was incubated with 1 fig of poly(dI). 
poly(dC) (double-stranded, average length 262 bp) in a volume of 20 
~1 containing 25 mM HEPES-NaOH, pH 7.5, 5 mM M&l,, 2 mM 
dithiothreitol and .50 mM NaCl at 25 “C for 10 min. NcoI-BamHI 
fragment (10,000 cpm) was then added and incubation continued for 
another 30 min. After incubation, 2 ~1 of loading buffer (0.05% 
hromphenol blue in 50% glycerol) was added, and the samples were 
analyzed by electrophoresis on 6% polyacrylamide gel (acrylamide to 
his ratio, 3O:ll in a low ionic strength buffer (6.7 mM Tris-HCI, pH 
7.5. 3.3 mM sodium acetate and 1 mM EDTA) at 4 “C for 3 h (10 
volts/cm). The gel was then soaked in 10% glycerol, dried, and 
subjected to autoradiography. 
Southwestern Blot Ano/>sls-Nuclear extracts (100 pg of protein) 
were analyzed on sodium dodecyl sulfate-polyacrylamide gel electro- 
phoresis (8% polyacrylamide), and the proteins were electrophoreti- 
tally transferred to a nitrocellulose membrane in a buffer containing 
25 mM Trizma base and 190 mM glycine for 16 h at 100 mA. The 
filters were first incubated with blocking buffer (2% nonfat dry milk, 
1% bovine serum albumin, 10 mM HEPES-NaOH, pH 7.5, 0.1 mM 
EDTA, 60 mM NaCl, 100 mM MgCIL, and 16 pg/ml sonicated salmon 
sperm DNA) for 2 h at room temperature. The filters were then 
incubated in binding buffer (same as blocking buffer but containing 
only 0.2% nonfat dry milk) containing nick-translated NcoI-RamHI 
upstream fragment (10” cpm/ml) for 2 h, washed, and subjected to 
autoradiography (9). 
Cytochrome P-4506 Protein Content-This analysis was carried out 
by radial immunodiffusion using cytochrome P-45Obspecific anti- 
body as described by Thomas et al. (18). Purified cytochrome P-4506 
was used as standard. 
RESULTS 
The effect of different concentrations of Dex on PB-me- 
diated induction of cytochrome P-450b+e mRNA was assessed 
by dot blot analysis using pP-450-91 probe. The results pre- 
sented in Fig. 1 indicate a potentiating effect of Dex at a 
concentration of 50 mg/kg body weight on the changes elicited 
by PB. The effects are less pronounced at Dex concentrations 
of 10 and 20 mg/kg (data not presented). Quantitative analysis 
of the dots presented in Fig. 1 indicate that Dex, PB, and 
PB+Dex enhanced cytochrome P-450b+e mRNA levels by 
2.5-, 8-, and 14-fold, respectively. Even at a Dex concentration 
of 80 mg/kg, the enhancement did not change significantly. 
2 
C Pi3 Dex 
A 
PB + Dex PB+Dex PB+ Dex 
FIG. 1. Dot blot analysis of cytochrome P-450b+e mRNA 
concentration in polyribosomes of adult rat livers treated with 
phenobarbitone and dexamethasone (50 mg/kg), for a period 
of 6 h. Polyrihosomal RNA (IO pg) was loaded onto nitrocellulose 
filters and hybridized with nick-translated pP-450e-91 DNA. Lane A: 
1, control (35): 2, PB (305); 3, Dex (69). Lane B represents three 
different groups treated with PB+Dex, each group consisting of two 
rats, 1 (510); 2 (423); 3 (535). The values given in parentheses 
represent the radioactivity (cpm) measured after punching out the 
dots from the nitrocellulose sheets. 
The results obtained on the concentrations of cytochrome P- 
450b and e mRNAs separately under these conditions, using 
specific oligonucleotide probes are presented in Table I. The 
potentiating effects of PB+Dex are quite evident, although 
the effect on cytochrome P-450b mRNA concentration is more 
marked than that on the e species. The results presented in 
Fig. 2 indicate that in 5-day-old pups, PB+Dex treatment 
fails to show any potentiating effect on cytochrome P-450b+e 
mRNA concentration. On the contrary, Dex inhibits the PB- 
mediated increase. 
Run-off transcription of cytochrome P-450b+e mRNAs was 
then carried out with nuclei isolated from PB- and Dex- 
treated adult and pup rat livers. The results presented in 
Table II reveal some interesting features. Quite unexpectedly, 
Dex inhibits the PB-mediated increase in cytochrome P- 
450b+e mRNA transcription by 60-70% in both adult and 
pup rat liver nuclei. Dex injection to saline-treated controls 
has no significant effect. Thus, while Dex inhibits the PB- 
mediated increase in cytochrome P-450b+e mRNA levels as 
well as run-off transcription in pups, it has the unusual effect 
of increasing the mRNA levels, while inhibiting transcription 
in the adult rat liver. 
To further elucidate the mechanism of action of Dex in 
adult rats, attempts were made to examine the transcription 
TABLE I 
Quantification of cytochrome P-4506 and e mRNAs using specific 
oligonucleotide probes 
The specific oligonucleotide probes described by Omiecinski et al. 
(13) were synthesized and end labeled with [y-““PIATP. Dot blot 
analysis was carried out with 20 pg of total polysomal RNA isolated 
from the livers of adult rats given the different treatments for a period 
of 6 h. The specificity of the probe for cytochrome P-4506 or e species 
was established by the ability of the corresponding excess cold oligo- 
nucleotide to chase the radioactive signal obtained with the radioac- 
tive probe. The spots were punched out from the nitrocellulose filter 
and radioactivity measured. 
mRNA content 
Treatment 
Cytochrome P-450b Cytochrome P-450e 
cpm 
Control 35 28 
PB 223 143 
Dex 46 33 
PB + Dex 436 225 
C 
2 
PB 
B f@ 
PB+Dex PB+Dex PB+Dex 
FIG. 2. Dot blot analysis of cytochrome P-450b+e mRNA 
concentration in polyribosomes of B-day-old rat livers treated 
with phenobarbitone and dexamethasone (50 mg/kg), for a 
period of 6 h. The experimental details are as given in text and Fig. 
2. 20 pg of polyribosomal RNA was used for analysis. Lane A, 1, 
control (55); 2, PB (620); 3, Dex (83). Lane B represents three 
different groups treated with PB+Dex, each group consisting of four 
rats: 1 (115); 2 (43); 3 (51). The values given in parentheses represent 
the radioactivity (cpm) measured after punching out the dots from 
the nitrocellulose sheets. 
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of an added cloned gene fragment under conditions of PB and 
Dex treatment. We have recently shown that pP-450-e4 DNA 
containing -179 bp of 5’-flanking region and a portion of the 
first exon can be faithfully transcribed in freeze-thawed rat 
liver nuclei. The transcripts analyzed by S, nuclease mapping 
using the end-labeled NcoI-EcoRI fragment reveal protected 
fragments of size 170 and 152 bp generated by exogenous and 
endogenous gene transcripts, respectively. The difference in 
the size of the protected fragments in the two cases is due to 
the contribution by transcription and protection of the poly- 
linker region in the case of added gene fragment and the 
absence of such a polylinker region in the endogenous gene 
(9). The results presented in Fig. 3 indicate interesting fea- 
tures. In the absence of added cloned gene fragment, PB 
treatment shows a striking increase in the S-protected band 
due to the endogenous P-450b+e gene transcripts (152 bp). 
Dex has a marginal effect, and, surprisingly, PB+Dex treat- 
ment has an effect almost similar to that of PB. When the 
cloned gene fragment is added, once again PB treatment 
shows an increase in the protected band resulting from the 
exogenous DNA transcript (170 bp), but Dex inhibits this 
increase very significantly. It may be pointed out that addition 
of exogenous DNA decreases the S-protected lower band 
arising due to endogenous gene transcription. 
We have recently identified a transcription factor(s) inter- 
acting with the 5’-flanking region of the cytochrome P- 
450b+e gene by gel retardation assay and Southwestern blot 
analysis. The binding of this factor(s) correlates very well 
TABLE II 
Effect of phenobarbitone and dexamethasone treatments on 
qtochrome P-kiOb+e mHNA run-off transcription 
The experimental details are given in the text. The animals were 
killed 6 h after drug treatment, and run-off transcription was carried 
out with isolated nuclei. The RNA transcripts (10’ cpm) were hybrid- 
ized to 5 pg of pP-4.5091 DNA loaded onto nitrocellulose filters. The 
hybridization efficiency was around 50%. The results presented rep- 
resent an average obtained from two independent experiments. 
Cytochrome P-45Ob+r 
Treatment mRNA transcription 
Adults Pups 
cpm 
Control 38 32 
PB 674 423 
Dex 47 43 
PB+Dex 183 93 
A 
FK. 3. Effect of phenobarbitone 
and dexamethasone treatment on 
the transcription of the endogenous 
cytochrome P-4506+e genes and the 
added pP-450e4 DNA. Freeze-thawed 
nuclei were incubated with or without 
added DNA as described in the text. The 
RNA transcripts were analyzed by S, 
nuclease protection assay. The top (170 
bp) and bottom (152 bp) bands are pro- 
tected DNA fragments arising from 
RNA transcripts derived from exogenous 
and endogenous gene fragments respec- 
tively. Pane/ A (endogenous run-off tran- 
scription): [one I, control; lane 2, PB; 
lane 3, Dex; lane 4, PB+Dex. Panel B 
(pP-450e4 DNA transcription): lane 1, 
control; lane 2, PB; lane 3, Dex; lane 4, 
PB+Dex. 
with the transcription status of the gene (9). It was, therefore, 
of interest to examine the effect of Dex treatment on the PB- 
mediated increase in the binding of the transcription factor(s) 
to the 5’-flanking region. Gel retardation experiments were 
performed with the NcoI-BamHI fragment labeled at the NcoI 
end and nuclear extracts prepared from rats given different 
treatments. The results presented in Fig. 4, A and B indicate 
the identification of at least two retarded complexes generated 
by the upstream fragment. The pattern generated depends 
upon the protein concentration of the nuclear extract and the 
nature and concentration of the competitor DNA used. It is, 
however, clear that PB treatment leads to a striking increase 
in the intensity of the lower band compared with control. At 
the higher protein concentration (3 pg of protein), the upper 
band shows a striking increase in intensity in the control, 
whereas the lower band shows a striking increase in intensity 
in PB treatment. Dex treatment counteracts the effects of PB 
treatment and leads to a decrease in the intensity of the lower 
band with a concomitant increase in the intensity of the upper 
band. Dex treatment per se gives a pattern, which is somewhat 
intermediate between control and PB treatment. The sig- 
nificance of these changes is as yet unclear, although there 
appears to be an inverse relationship between the formation 
of the upper and lower complexes. It is clear, however, that 
PB treatment gives rise to a characteristic gel retardation 
pattern and Dex treatment counteracts this effect. 
The nuclear proteins were then analyzed on sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis, transferred to ni- 
trocellulose and then probed with labeled NcoI-BumHI up- 
stream fragment. The results presented in Fig. 5 indicate a 
striking increase in a set of protein bands after PB treatment, 
the maximum response being with the band of M, 90,000 + 
5,000. Dex treatment clearly inhibits this PB-mediated in- 
crease. We had earlier assessed the molecular weight of this 
species responding to PB treatment as 85,000 (9) and a 
revision is now made on the basis of mobility studies in several 
gels run with standard markers. 
Finally, attempts were made to examine the effects of Dex 
on the stability of cytochrome P-450b+e mRNAs induced by 
PB. For this purpose, the animals received a single injection 
of PB after 6 h, fresh transcription was blocked with CoCl? 
or actinomycin D. CoCIL was used as a specific inhibitor of 
cytochrome P-450b+e mRNA transcription (6, 15) and acti- 
nomycin D as a general inhibitor of transcription. Cytochrome 
P-450b+e mRNA was quantified in polyribosomes by dot blot 
B 
12 3 4 12 3 4 
-170bP 
-152bP 
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5620 Effect of Dexamethasone on Cytochrome P-450b/e Gene Expression 
A B 
12 3 4 5 1 2 3 4 
eor,lyw,Qy) G-FREE DNA 
FIG. 1. Gel retardation analysis of the interaction between nuclear extract and “2P-end labeled 
upstream region (NcoI-BumHI fragment). The experimental details are given in text and 1.5 pg (A) and 3 pg 
IH) of protein were used. Lane I, control: lane 2, PB; Iane 3. Dex; lane ?, PB+Dex; lane 5, free DNA. 
1 2 3 4 
. 
analysis at different time intervals after transcription arrest. 
The results presented in Fig. 6 indicate that the half-life of 
PB-induced cytochrome P-450b+e mRNA is not significantly 
changed after Dex treatment, even though the content of 
these mRNAs is higher in PB+Dex treatment than in PB 
treatment. Similar results were obtained with CoCl:, or acti- 
nomycin D treatments. 
We have quantified the levels of cytochrome P-4506 protein 
under the different treatment conditions using radial-immu- 
nodiffusion. The results reveal that there is a small increase 
in cytochrome P-4506 protein content after Dex treatment 
compared with controls. PB treatment results in a significant 
increase, whereas PB+Dex treatment actually shows a slight 
decrease compared with the former (cytochrome P-450b pro- 
tein content in nmol/mg protein: control, not detectable; PB, 
1.01; Dex, 0.16; PB+Dex, 0.81). As already pointed out, Sim- 
mons et al. (10) have shown that Dex treatment per se 
increases cytochrome P-450b mRNA levels by nearly 12.fold, 
but there is no concomitant increase in the protein levels. 
0 I 2 3 
i,me (tlr) 
FIG. 6. Effect of dexamethasone treatment on the stability 
of cytochrome P-4506+e mRNAs induced by phenobarbitone. 
Fro. 5. Southwestern blot analysis of nuclear extracts. NcoI- The experimental details are given in text. CoC1, or actinomycin D 
HntnHI fragment was used as a probe. Lane I, control: lane 2, PB; was given G h after phenobarbit.one injection to block fresh cyto- 
lane .‘I. Dex: Ianc -/, PB + Dex. The arrm corresponds to the protein chrome P-450b+e mRNA transcription. The specific mRNAs were 
band of M, 90,000 f .5,000. The intense bands seen at the bottom are quantified by dot blot analysis of polyribosomal RNA (20 pg), hybrid- 
due to histones. Cold marker proteins were run for molecular weight ization, and measurement of radioactivity of the dots. The data 
calibration. obtained at 6 h are taken as the zero time values. The results presented are an average obtained from two independent experiments. 
-, CoCl? treatment; - - actinomycin D treatment. 
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Effect of Dexamethasone on Cytochrome P-450b/e Gene Expression 
They have considered various possibilities such as induction 
of a species in the cytochrome P-450b mRNA family hybrid- 
izing to the probe but the protein species weakly cross- 
reacting with the b antibody, selective degradation of the 
protein species and a Dex-inducible translation inhibitor. 
These possibilities need to be examined for the results ob- 
tained with PB and PB+Dex treatments in the present in- 
vestigation. However, in the present study, Dex treatment 
alone shows a small increase in cytochrome P-450b protein 
content compared with controls. 
DlSCUSSlON 
Dex is well known to act as a positive modulator of certain 
genes and exerts its effects through the glucocorticoid receptor 
interacting with glucocorticoid responsive elements, GRE 
(19-21). Negative regulation of transcription of certain eu- 
karyotic genes is also clearly documented (22-25), although 
the mechanistic relationships between positive and negative 
effects are not very clear. 
In the present study, Dex has been shown to negatively 
modulate the PB-mediated activation of cytochrome P- 
450b+e gene transcription. Two significant points emanate 
out of this study. One is that Dex shows a potentiating effect 
with PB on cytochrome P-450b+e mRNA levels, although it 
negatively modulates their transcription. Simmons et al. (10) 
have shown that Dex (80 mg/kg) by itself enhances cyto- 
chrome P-450b+e mRNA levels in rat liver by 12-fold without 
significantly influencing their transcription rates. They have 
suggested the possibility of mRNA stabilization. We have not 
been able to obtain 12-fold induction of cytochrome P-450b+e 
mRNA by Dex even under conditions described by Simmons 
et al. (lo), perhaps due to strain variation. Under the condi- 
tions of our experimentation, Dex induces cytochrome P- 
450b+e mRNA levels by 2.5-fold without having a significant 
effect on basal transcription. However, Dex shows a poten- 
tiating effect with PB on the induction of cytochrome P- 
450b+e mRNA levels but does not manifest any stabilization 
effect at the cytoplasmic level. However, it appears that Dex 
may be stabilizing the cytochrome P-450b+e mRNA tran- 
scripts in the nuclei. This is evident from the S, nuclease 
protection analysis of endogenous P-450b+e gene nuclear 
transcripts (Fig. 3A). The RNA isolated from the nuclei under 
these conditions consists of steady state cytochrome P-450b+e 
mRNA transcripts in addition to a small amount of fresh 
transcripts. If PB+Dex treatment has stabilized the nuclear 
transcripts derived from the endogenous cytochrome P- 
450b+e gene during the period of treatment, even though 
fresh transcription is inhibited by 60-70%, S, nuclease pro- 
tection analysis would not reveal a significant decrease com- 
pared with nuclei derived from PB-treated livers. An attempt 
was also made to measure the half-life of nuclear cytochrome 
P-450b+e mRNA transcripts under conditions described in 
Fig. 6 for the measurement of half-life of cytoplasmic cyto- 
chrome P-450b+e mRNA. The results did indicate a longer 
half-life for the cytochrome P-450b+e nuclear RNA tran- 
scripts under conditions of PB+Dex treatment than in PB 
treatment (data not presented). However, the differences 
obtained were small, and therefore the conclusions based on 
this experiment can only be considered tentative but support 
data obtained with S1 nuclease protection analysis. At the 
same time, it is clear that Dex inhibits the synthesis of fresh 
transcripts induced by PB as evidenced by run off transcrip- 
tion experiments using [(u-“‘P]UTP or S1 nuclease protection 
analysis of fresh transcripts synthesized in response to the 
addition of cloned gene fragment to nuclei. 
As already mentioned, transcription of added cloned gene 
fragment is accompanied by a suppression of the S-protected 
band due to endogenous cytochrome P-450b+e gene tran- 
script, both in PB as well as PB+Dex treatments (Fig. 4B). 
In this particular experiment, the suppression seen is about 
50% in the case of nuclei isolated from PB-treated rats and 
is nearly 95% in the case of nuclei isolated from PB+Dex- 
treated rats (compare S1 nuclease-protected band in Fig. 4A 
with the lower band in Fig. 4B). It may, however, be pointed 
out that the suppression level seen in endogenous transcripts 
due to the addition of exogenous gene is variable and a high 
level of suppression has been obtained in nuclei from PB- 
treated animals as well in other experiments. It appears 
possible that the entire nuclear mRNA transcript is template 
bound and addition of excess of cloned gene fragment may 
bind all the available transcription factors. This can lead to 
an arrest of the endogenous gene transcription accompanied 
by degradation of the template bound transcripts, resulting 
in a striking decrease in the generation of S-protected band. 
In 5-day-old pups, Dex inhibits PB-mediated increase in 
transcription of cytochrome P-450b+e mRNA as well as their 
levels in the cytoplasm. Thus, the stabilization effect of Dex 
is seen only in adults and therefore is developmentally pro- 
grammed. 
The second significant point is on the mechanism by which 
Dex negatively modulates PB-mediated activation of cyto- 
chrome P-450b+e mRNA transcription. Three different types 
of observations have been made in attempts to explain nega- 
tive modulation of transcription by glucocorticoids. Sakai et 
al. (25), in a study with bovine prolactin gene, have proposed 
that the glucocorticoid receptor can bind both positive and 
negative GREs, which are distinct elements, giving rise to 
alternate conformations resulting in positive or negative ef- 
fects. Additionally, they have shown that in the absence of 
glucocorticoids or the receptor, the negative GRE acts as a 
constitutive enhancer-like element activating transcription, 
perhaps due to the binding of an activator protein. Receptor 
binding at the negative GRE is visualized to reverse the 
constitutive enhancer action presumably by removing or oth- 
erwise neutralizing the actions of the enhancer activating 
protein bound at an overlapping site. In another study, Langer 
and Ostrowski (26), have examined the effect of negative 
GRE from mouse mammary tumor virus gene in cell-free 
assay. According to these workers, negative GRE binds a 
repressor protein distinct from the glucocorticoid receptor 
and decreases the basal level of transcription from some 
glucocorticoid-regulated promoters by preventing the assem- 
bly of active transcription complexes at promoter elements 
such as CCAAT box and TATA box. Oro et al. (28) have 
shown that trans-repression by human glucocorticoid receptor 
may involve a steric hindrance mechanism wherein the car- 
boxyl-terminal domain of the receptor inhibits activation by 
preventing other factors from binding to the promoter or 
interacting with the transcription machinery. Despite the 
differences in the experimental systems used and the conse- 
quence of results, the common feature is that functional 
manifestation of negative GRE involves interference with the 
assembly of an activation complex at the enhancer or pro- 
moter site. In that respect, the present study also indicates 
that Dex administration counteracts the binding of the PB- 
activated transcription factor(s) to the 5’-flanking region of 
the cytochrome P-450ble gene. As already indicated, this 
binding correlates very well with the transcription status of 
the gene, as evidenced by the results obtained in the present 
study and elsewhere (9). 
A tentative model can be proposed as follows. The cyto- 
chrome P-450b+e gene transcription is in the repressed state 
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5622 Effect of Dexamethasone on Cytochrome P-450b/e Gene Expression 
in the normal animal. This may be due to a repressor protein 
functioning independent of Dex. Dex may not have any ad- 
ditional repressive effect, since the gene is already in a re- 
pressed state. In fact, Dex treatment shows a small increase 
in mRNA and protein contents. Administration of PB results 
in the augmented synthesis of a positive transcription fac- 
tor(s), that can reverse the effect of the repressor. Adminis- 
tration of Dex can recruit the receptor or some other Dex- 
modulated protein to bind at the negative GRE that may once 
again reverse the effects of the positive transcription factor(s) 
induced by PB. At this stage it is not clear whether Dex exerts 
its negative effects at the level of transcription through its 
receptor or some other Dex-modulated protein. The present 
study has shown that Dex has a negative effect in &day-old 
pups as well, where the glucocorticoid receptor levels are low. 
Thus, the involvement of some other Dex-modulated protein 
cannot be ruled out. A similar possibility has been suggested 
to explain the positive modulation effects of Dex on the 
transcription of cytochrome P-450pcn gene (27). The negative 
GRE may include or be very close to the sites for the binding 
of the repressor as well as the receptor/Dex-modulated protein 
as is the case in other systems where the negative GRE has 
sites for binding an activator or repressor (25, 26). The 
negative modulating effects of Dex at the level of transcription 
are clearly evident from its efficacy to counteract the effects 
of PB on cytochrome P-450b+e gene transcription as well as 
the binding of specific nuclear proteins to the 5’-flanking 
region of the gene as demonstrated by gel retardation and 
Southwestern blot analysis. We have identified a footprint 
for the positive transcription factor(s) induced by PB in the 
region -56 to -88 that includes a consensus nuclear factor I- 
binding site and a 13-bp pseudopalindrome (9). The region 
-122 to -150 includes the two TGTCCT repeats, and it is 
known that the different negative GREs identified do not 
closely conform to each other or to the positive GRE in terms 
of consensus sequence (25). It would be of interest to identify 
the negative GRE of the cytochrome P-450b+e genes and 
further examine the modalities of this negative regulation. 
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